TORONTO, November 17, 2010 – Canadians are unaware of dangers that may be lurking in prescription drugs, which aren’t sufficiently tested or monitored, says a report issued today by the Health Council of Canada, and headed by York University researchers.
Keeping an Eye on Prescription Drugs, Keeping Canadians Safe, calls for sweeping improvements to drug safety in Canada, highlighting the following little-known facts:
- Over the past 25 years the percentage of drugs that were withdrawn from the market has not changed, however, the number of people exposed to unsafe drugs has been increasing.
- Many Canadians are uninformed about safety issues with drugs currently on the market.
- Pre-market testing provides information about the benefits of drugs but does not establish a full safety profile; it is conducted by pharmaceutical companies in a short period of time with a small number of patients.
- There are no regulatory requirements for drug companies to conduct additional research on product safety once their drug has entered the market.
- Health Canada cannot require companies to conduct post-market studies and cannot order changes to drug labels after a product has been approved unless new significant safety issues are identified.
- Although Health Canada has the authority to order drugs to be withdrawn from the market, they rarely exercise this power.
The paper’s lead authors are Mary Wiktorowicz and Joel Lexchin, professors in York’s School of Health Policy and Management, Faculty of Health; it is co-authored by Kathy Moscou of the University of Toronto’s International Pharmacy Graduate Program.
Lexchin notes two drugs that were widely promoted and prescribed in 2000 – BaycolTM and VioxxTM – were withdrawn due to safety issues. “Roughly 16 million prescriptions for Vioxx had been written in Canada by the time it was taken off the market,” he says.
Their comparative analysis of Canada, the United States, Britain, France, the European Union and New Zealand found an array of policy approaches being adopted internationally and emphasizes the manner in which the governance of post-market surveillance systems can be enhanced.
John G. Abbott, CEO, Health Council of Canada, remarks that the public may think a drug approved by Health Canada is always safe. “What Canadians don’t know about are the limitations in our current pre-market testing and the lack of surveillance once a drug has entered the market,” he says.
Among the report’s recommendations:
- Wide dissemination of drug safety messages, including monitoring and evaluation of messaging.
- Health Canada should have the authority to impose penalties for failure to complete post-market safety studies.
- Post-market research should be registered, transparent, free from conflicts of interest and the results made available to the public.
- There should be broad stakeholder involvement in decision-making concerning publicly commissioned post-market studies.
-30-
York University is the leading interdisciplinary research and teaching university in Canada. York offers a modern, academic experience at the undergraduate and graduate level in Toronto, Canada’s most international city. The third largest university in the country, York is host to a dynamic academic community of 50,000 students and 7,000 faculty and staff, as well as 200,000 alumni worldwide. York’s 10 Faculties and 28 research centres conduct ambitious, groundbreaking research that is interdisciplinary, cutting across traditional academic boundaries. This distinctive and collaborative approach is preparing students for the future and bringing fresh insights and solutions to real-world challenges. York University is an autonomous, not-for-profit corporation.
Media Contact:
Melissa Hughes, Media Relations, York University, 416 736 2100 x22097, mehughes@yorku.ca
